Alliance Global raised the firm’s price target on Capricor Therapeutics (CAPR) to $48 from $16 and keeps a Buy rating on the shares after the company read out topline data for their pivotal Phase 3 HOPE-3 trial of Deramiocel in 106 Duchenne Muscular Dystrophy patients. These data were unequivocally and wholly positive, in the firm’s view. Alliance Global is removing its speculative tag.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR: